MetLife Investment Management, LLC - Aug 4, 2020 Form 4 Insider Report for Neuberger Berman High Yield Strategies Fund Inc. (NHS)

Role
10%+ Owner
Signature
/s/ Israel Grafstein, Chief Compliance Officer of MetLife Investment Management, LLC
Stock symbol
NHS
Transactions as of
Aug 4, 2020
Transactions value $
-$1,264,884,481,362,865
Form type
4
Date filed
6/10/2022, 04:30 PM
Previous filing
May 26, 2022
Next filing
Jun 10, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NHS Floating Rate Senior Note, Series A Note, Due Sep. 18, 2023 Other -$255T -16M -66.67% $15,992,744.26* 7.98M Aug 4, 2020 See Footnotes F1, F3, F4, F5
transaction NHS Floating Rate Senior Note, Series A Note, Due Sep. 18, 2023 Other -$311T -17.6M -66.67% $17,647,166.12* 8.81M Aug 4, 2020 See Footnotes F1, F3, F4, F5
transaction NHS Floating Rate Senior Note, Series A Note, Due Sep. 18, 2023 Other -$698T -26.4M -66.67% $26,448,050.45* 13.2M Aug 4, 2020 See Footnotes F1, F3, F4, F5
transaction NHS Series B Mandatory Redeemable Preferred Shares Other -$49.1B -1.4K -100% $35,092,143.82* 0 Aug 4, 2020 See Footnotes F2, F3, F4, F5
transaction NHS Series C Mandatory Redeemable Preferred Shares Purchase $62M +4.96M $12.50 4.96M Aug 4, 2020 See Footnotes F4, F5
transaction NHS Series C Mandatory Redeemable Preferred Shares Purchase $12M +960K $12.50 960K Aug 4, 2020 See Footnotes F4, F5
transaction NHS Series C Mandatory Redeemable Preferred Shares Purchase $21M +1.68M $12.50 1.68M Aug 4, 2020 See Footnotes F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These Floating Rate Senior Notes, Series A Notes, due September 18, 2023 ("Notes") were redeemed, in part, by the Issuer pursuant to a partial prepayment of the principal plus accrued and unpaid interest.
F2 These Series B Mandatory Redeemable Preferred Shares ("Series B MRPS") were redeemed, in whole, by the Issuer at a price equal to the liquidation preference of $25,000 per share plus accumulated and unpaid dividends.
F3 This price reflects the aggregate amount received in exchange for the redemption.
F4 These Notes, Series B MRPS and Series C MRPS are held directly by clients for whom the Reporting Person serves as investment manager.
F5 The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Remarks:

The initial Form 3 was filed on October 9, 2013 by Metropolitan Life Insurance Company. Subsequent to that filing, management of positions in the Issuer's securities was transferred to MetLife Investment Management, LLC, who assumed the Section 16 reporting obligations for such positions.